COPENHAGEN, Denmark, July 23, 2024 /PRNewswire/ --          Delivering our highest ever quarterly sales amounting to USD 217 million Organic growth of 6% for Q2 driven strong performance in Prosthetics & Neuro Orthotics and Patient Care EBITDA was USD 47 million and EBITDA margin was 22% for Q2 Medicare in the US has finalized a proposal that grants active K2 patients access to prosthetic knees New exciting innovation launched in bionics with NAVii® by Össur and Icon® by College Park Announcement no. 11/2024Interim report Q2 202423 July 2024 Sveinn Sölvason, President and CEO, comments: "We delivered our highest ever quarterly sales in Q2 2024 with sales amounting to USD 217 million. Organic growth was 6% for Q2 and local currency growth 9% with continued strong momentum in EMEA, driven by a strong performance in Prosthetics & Neuro Orthotics and Patient Care. In our Bracing & Supports business growth was more modest for the quarter. Our EBITDA margin came in strong for the quarter at 22%, supported by the cost reduction initiatives implemented in manufacturing in addition to a contribution from positive product mix and scalability. Toward the end of the quarter we introduced two new bionic knee products, NAVii® by Össur and Icon® by College Park, and we are very excited about their potential in improving people's mobility. Medicare in the US has finalized a proposal which will create a pathway for K2 amputees, which account for a significant part of the amputee population, to utilize more functional knee and foot solutions than they have historically had access to. This is great news, and we look forward to helping these individuals become more active and able in their daily activities. We are executing well on our Growth'27 strategy. We are narrowing our full-year guidance ...